Online inquiry

IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10209MR)

This product GTTS-WQ10209MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ITGA4&ITGB7 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000885.6; NM_000889.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3676; 3695
UniProt ID P13612; P26010
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ10209MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6719MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA DS 1024
GTTS-WQ5778MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ10183MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LC1004-002
GTTS-WQ7839MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ10532MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ623MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ10733MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA M-281
GTTS-WQ11394MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-575
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW